Colon cancer drug seen as long-awaited victory
The first drug to emerge from a Harvard surgeon's 34-year crusade for a new class of cancer treatments is expected to win approval within weeks from the Food and Drug Administration, validating a field of research that now embraces more than 35 diseases ranging from Alzheimer's to psoriasis, researchers said. (Full Article: 1250 Words)
This article is available in our archives:
Globe Subscribers
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 Article
- $9.95 4 Articles
- $99.95 Unlimited





